Clinical trials: completed, in Iran
Obesity & Overweight
Spartina® (Tirzepatide) Effectiveness and Safety Evaluation
The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered: 1.
- Trial name
- NCT07262762
- Where
- 14 sites in Iran
- Volunteers
- 175 people
- Sponsor
- Cinnagen
Ischemic Stroke, Stroke
Gravity Stent-Retriever System For Reperfusion Of Large Vessel Occlusion Stroke Trial
The study aims to evaluate the safety and efficacy of the Supernova stent retriever device, developed by Gravity Medical Technology, for treating acute ischemic stroke.
- Conditions
- Ischemic Stroke, Stroke, Cerebrovascular Disorders, Brain Diseases
- Trial name
- GRASSROOT (NCT06249776)
- Testing
- Supernova revascularization device
- Where
- 11 sites in India, Iran and 1 more
- Volunteers
- 55 people
- Sponsor
- Gravity Medical Technology, INC
Moderate or Severe Nasolabial Folds
Effectiveness and Safety Comparison of Lunaphil Ultra (Hyaluronic Acid, by Espad Pharmed Co.) Versus Juvederm Ultra 4® (Hyaluronic Acid, by Allergan Co.) in Nasolabial Folds (NLFs) Management
Rationale and background: Skin aging is a complex process that results in various changes in the skin, including wrinkles, sun spots, and sagging skin.
- Trial name
- NCT06509477
- Testing
- Hyaluronic acid Lunaphil Ultra (by Espad Pharmed Co.), Hyaluronic acid Juvederm Ultra 4® (by Allergan Co.)
- Where
- Iran
- Volunteers
- 104 people
- Sponsor
- Espad Pharmed
Flank Fat
Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) for the Treatment of Flank Fat
Flank region fat is a factor affecting beauty that makes people feel uncomfortable about themselves. In 2015, deoxycholic acid was approved by the American FDA for treatment of flank fat.
- Trial name
- NCT07004010
- Testing
- Deoxycholic Acid Injection
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Espad Pharmed
Ulcerative Colitis (UC), Crohn Disease (CD)
VedAryo® (Vedolizumab) Effectiveness and Safety Evaluation
The aim of this observational study is to evaluate Effectiveness and safety of VedAryo® (Vedolizumab) in male or female participants with clinical diagnosis of Inflammatory Bowel Disease. The main questions are aim to answer: 1.
- Conditions
- Ulcerative Colitis (UC), Crohn Disease (CD), Inflammatory Bowel Disease (IBD)
- Trial name
- NCT07273760
- Testing
- Vedolizumab
- Where
- 12 sites in Iran
- Volunteers
- 150 people
- Sponsor
- AryoGen Pharmed Co.
Submental Fullness
Effectiveness and Safety Evaluation of Embella (Deoxycholic Acid, by Espad Pharmed Co.) in Management of Submental Fat
Submental fat (SMF) is a factor affecting beauty that makes people feel uncomfortable about themselves. In 2015, deoxycholic acid with the brand name KYBELLA® was approved by the American FDA for treatment of submental fat.
- Trial name
- NCT06509438
- Testing
- Embella (Deoxycholic acid, produced by Espad Pharmed Co.)
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Espad Pharmed
Keratoconus
Evaluation of Safety and Efficacy of a Bioengineered Corneal Implant for Treatment of Keratoconus
This is a prospective, Phase I open-label safety study to evaluate the safety, feasibility and initial efficacy of a bioengineered corneal stromal substitute after implantation into the stroma of adults with advanced keratoconus.
- Trial name
- LinkCor (NCT04653922)
- Testing
- LinkCor Bioengineered Corneal Implant
- Where
- 2 sites in India, Iran
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- LinkoCare Life Sciences AB
Alopecia Totalis/Universalis, Alopecia Areata(AA)
Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation
The goal of this observational study is to evaluate safety of Rhofanib® (Tofacitinib) in male or female participants with the age of 18 years or older having clinical diagnosis of Alopecia.
- Trial name
- NCT07101471
- Testing
- Tofacitinib
- Where
- Iran
- Volunteers
- 296 people
- Sponsor
- NanoAlvand
Nasolabial Fold Correction
Evaluation of Efficacy and Safety of Intella Dermal Filler in Moderate to Severe Nasolabial Folds
This single-arm, before-and-after clinical trial evaluated the safety and efficacy of Intella, a combined CaHA and HA dermal filler manufactured by Espad Pharmed Darou Co., for the correction of moderate to severe nasolabial…
- Trial name
- NCT07102537
- Testing
- Hyaluronic acid combined with calcium hydroxyapatite injection
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Espad Pharmed
Glabellar Lines, Glabellar Frown Lines
A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines
The aim of this study is to evaluate the efficacy and safety of AbobotulinumtoxinA (produced by Espad Pharmed Darou Co.) for correction of moderate to severe glabellar lines.
- Trial name
- NCT06946160
- Testing
- Abobotulinumtoxin A (Espad Pharmed Darou Co.), Abobotulinumtoxin A (Ipsen Co.)
- Where
- Iran
- Volunteers
- 146 people
- Sponsor
- Espad Pharmed
Skin Aging
Evaluation of Effectiveness and Safety of Stabilized Injectable Hyaluronic Acid (Perleux Body, Produced by Espad Pharmed Company) in the Neck Area
This study aimed to evaluate the safety and effectiveness of stabilized Hyaluronic Acid Injection under the brand name Perleux body for neck skin rejuvenation, elasticity improvement, and hydration enhancement.
- Trial name
- NCT06844760
- Testing
- Hyaluronic Acid (HA)
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Espad Pharmed
Mucopolysaccharidosis Type 1
Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients
The purpose of this phase III study is to assess the efficacy and safety of YW17 produced by CinnaGen Company compared to Aldurazyme® in mucopolysaccharidosis type I (MPS I) patients.
- Trial name
- NCT06406153
- Testing
- Laronidase, Antihistamine, Antipyretic
- Where
- 4 sites in Iran
- Volunteers
- 12 people
- Sponsor
- Cinnagen
HER2-positive Breast Cancer
Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
This study was a phase III, multicenter, triple-blind, equivalency clinical trial to determine the therapeutic efficacy and safety between Pertuzumab® (CinnaGen Co.) compared to originator pertuzumab in HER2-positive early breast…
- Trial name
- NCT04957212
- Testing
- Trastuzumab, Pertuzumab, Carboplatin
- Where
- 44 sites in Iran
- Volunteers
- 214 people
- Sponsor
- Cinnagen
Malignant Neoplasm of Breast
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
This is A Phase III, randomized, two-armed, patient-outcome assessor-data analyzer blinded, parallel active controlled non-Inferiority clinical trial study to evaluate efficacy and safety of AryoTrust (Aryogen Trastuzumab in…
- Trial name
- NCT03425656
- Testing
- Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
- Where
- 19 sites in Iran
- Volunteers
- 108 people
- Sponsor
- AryoGen Pharmed Co.
Severe Hemophilia A
rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study
The study is designed as a randomized, two-armed, double-blind, single-dose, crossover, two-sequence, active-controlled, multi-center, bioequivalence clinical trial with a primary endpoint of dose-normalized area under the curve…
- Trial name
- NCT06137092
- Testing
- Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)
- Where
- 5 sites in Iran
- Volunteers
- 50 people
- Sponsor
- AryoGen Pharmed Co.
Breast Cancer
AryoTrust® (Trastuzumab) Safety Study
This study was a phase IV, observational, multicenter, single-arm, open-label, post-marketing surveillance study for the assessment of AryoTrust safety in Iranian HER2-positive breast cancer patients undergoing adjuvant…
- Trial name
- NCT06021379
- Testing
- Trastuzumab
- Where
- 15 sites in Iran
- Volunteers
- 597 people
- Sponsor
- AryoGen Pharmed Co.
COVID-19
Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine
This is an open-label, single-arm clinical trial designed to evaluate the immunogenicity and safety of a booster dose of an adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (SpikoGen) produced by CinnaGen Co.
- Trial name
- NCT05285384
- Testing
- SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
- Where
- Iran
- Volunteers
- 43 people
- Sponsor
- Cinnagen
Allergic Asthma, Uncontrolled Moderate to Severe
Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma
The purpose of this study is to evaluate the efficacy and safety of Omalizumab produced by CinnaGen compared with Xolair® (Genentech, Inc., USA And Novartis Pharmaceuticals Corp, Switzerland) in subjects with uncontrolled…
- Trial name
- NCT05813470
- Testing
- Omalizumab (CinnaGen), Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)
- Where
- 22 sites in Iran
- Volunteers
- 256 people
- Sponsor
- Cinnagen
Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration
Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration
The purpose of this study is to evaluate the efficacy and safety of Aflibercept (produced by CinnaGen Co, Iran) compared with Eylea® (Regeneron, USA) in subjects with Neovascular Age-related Macular Degeneration (nAMD).
- Trial name
- NCT05587062
- Testing
- Aflibercept (CinnaGen Co, Iran), Aflibercept (Regeneron, USA)
- Where
- Iran
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Cinnagen
Multiple Sclerosis, Relapsing-Remitting
Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis
The purpose of this study is to evaluate the efficacy and safety of Ocrelizumab produced by CinnaGen compared with Ocrevus® (Roche, Switzerland) in subjects with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT04966338
- Testing
- Ocrelizumab (CinnaGen, Iran), Ocrelizumab (Roche, Switzerland)
- Where
- 15 sites in Iran
- Volunteers
- 170 people
- Sponsor
- Cinnagen